Disease Atlas / Disease detail

Botulism

A guideline-led atlas of exposure types, neuroparalysis, diagnosis, antitoxin, respiratory support, and public-health response.

botulism · botulism · botulinum neurotoxin disease

MONDO:0005498Public QA completeSource-bound · 4

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · 234a20fed054

Disease class: Botulism is a rare but serious illness in which botulinum neurotoxin disrupts nerve function and causes flaccid paralysis.
Core mechanism: The toxin blocks acetylcholine release at the neuromuscular junction and produces muscle weakness.
Genes or cause: Foodborne, wound, infant, and rare iatrogenic or inhalational botulism differ in route of exposure and affected population.
Typical features: Diplopia, ptosis, dysarthria, or dysphagia followed by symmetric descending weakness is an important clinical pattern.
Variability: The combination and pace of symptoms can vary with toxin type, exposure amount, timing of care, and underlying health.
Diagnosis: Diagnosis begins with clinical assessment and can be confirmed by testing serum, stool, food, or wound specimens for toxin or organism.
Management: Antitoxin neutralizes circulating toxin but does not immediately reverse paralysis that has already developed.
Treatment and research: Severe respiratory muscle weakness can require prolonged airway and ventilatory support followed by rehabilitation.
Reading evidence: Rapid clinical response and coordination with public health authorities are important for identifying and preventing additional exposures.
Key caution: Because recovery of nerve terminals takes time, fatigue and weakness can persist in survivors.

A structured guide for understanding the disease and preparing for clinical conversations.

Botulism is a rare but serious illness in which botulinum neurotoxin disrupts nerve function and causes flaccid paralysis.

Diplopia, ptosis, dysarthria, or dysphagia followed by symmetric descending weakness is an important clinical pattern.

The toxin blocks acetylcholine release at the neuromuscular junction and produces muscle weakness.

Foodborne, wound, infant, and rare iatrogenic or inhalational botulism differ in route of exposure and affected population.

The combination and pace of symptoms can vary with toxin type, exposure amount, timing of care, and underlying health.

Diagnosis begins with clinical assessment and can be confirmed by testing serum, stool, food, or wound specimens for toxin or organism.

Antitoxin neutralizes circulating toxin but does not immediately reverse paralysis that has already developed.

Severe respiratory muscle weakness can require prolonged airway and ventilatory support followed by rehabilitation.

Treatment studies should be read by separating botulism type, timing of antitoxin, duration of respiratory support, and recovery outcomes.

Clinical discussions distinguish possible exposure, changes in breathing or swallowing, rehabilitation needs, and public-health test results.

This material is for disease education and is not a personal diagnosis or treatment instruction.

A trial registry status does not establish efficacy or regulatory approval.